ICD-10 Coding for Neuropathy due to Chemotherapy(E11.42, G62.0, G62.0B)
Learn about ICD-10 coding for neuropathy due to chemotherapy, including documentation requirements and coding tips for accurate billing.
Complete code families applicable to Neuropathy due to Chemotherapy
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| G62.0 | Drug-induced polyneuropathy | Use when neuropathy is directly linked to chemotherapy treatment. |
|
| T45.1x5* | Adverse effect of antineoplastic and immunosuppressive drugs | Use as a secondary code to specify the adverse effect of chemotherapy. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutNeuropathy due to Chemotherapy
Alternative codes to consider when ruling out similar conditions
Use when neuropathy is due to diabetes, not chemotherapy.
Documentation & Coding Risks
Avoid these common issues when documenting Neuropathy due to Chemotherapy.
Failure to document the causal relationship between chemotherapy and neuropathy
Impact
Clinical: Inaccurate diagnosis and treatment planning, Regulatory: Non-compliance with documentation standards, Financial: Potential claim denials or reduced reimbursement
Mitigation
Educate providers on documentation standards, Use templates to ensure comprehensive notes
Using G62.9 instead of G62.0 when chemotherapy link exists
Impact
Reimbursement: Potential underpayment due to incorrect coding, Compliance: Non-compliance with coding guidelines, Data Quality: Inaccurate clinical data representation
Mitigation
Query provider to confirm neuropathy is treatment-related.
Incorrect sequencing of codes
Impact
G62.0 must be primary with T45.1x5* as secondary.
Mitigation
Regular training on coding guidelines and sequencing rules.